GACM
ALNY icon

Green Arrow Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Green Arrow Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-50,000
Closed -$3.16M – 173
2014
Q2 		$3.16M Buy
+50,000
New +$2.97M 0.4% 73

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Green Arrow Capital Management's ALNY Position: Q2 2014 in Review

Green Arrow Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2014, closing a stake of 20,000 shares — an estimated $1.19M sold.

Green Arrow Capital Management first reported a position in ALNY in Q1 2014 and held it in 1 quarter. The position peaked at $1.34M in Q1 2014. 194 funds tracked by Wall St. Rank hold ALNY as of Q2 2014.

  • Green Arrow Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Green Arrow Capital Management sold 20,000 Alnylam Pharmaceuticals shares in Q2 2014, an estimated $1.19M.
  • Green Arrow Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Green Arrow Capital Management's Alnylam Pharmaceuticals position peaked at $1.34M in Q1 2014.
  • 194 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2014.

Based on Green Arrow Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.